Literature DB >> 10618761

Bisphosphonates: from grandparents to grandchildren.

T Srivastava1, U S Alon.   

Abstract

Bisphosphonates are synthetic analogues of pyrophosphate that inhibit bone resorption by their action on osteoclasts. Bisphosphonates have been extensively used in the elderly with primary and secondary osteoporosis, Paget's disease, and hypercalcemia of malignancy. In recent years, bisphosphonates have been used to treat children acutely for resistant hypercalcemia and chronically for various metabolic bone diseases. The theoretical concerns of possible adverse effects of these drugs on the growing skeleton have not been proven to be true. In the present review, we have critically analyzed the available literature on bisphosphonate therapy in both adult and pediatric clinical trials. Although not yet approved by the FDA for use in children, bisphosphonates, from published experience, demonstrate benefit to the child with no serious adverse effects. Based on the literature analysis the review furnishes detailed recommendations and practical guidelines regarding the use of oral and intravenous bisphosphonates in children. Bisphosphonates might be the first agents to provide the pediatrician with an opportunity to treat mineral and bone disorders of childhood, which until recently did not have satisfactory therapy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10618761     DOI: 10.1177/000992289903801201

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  6 in total

Review 1.  Hypercalcemia in children and adolescents.

Authors:  Steven A Lietman; Emily L Germain-Lee; Michael A Levine
Journal:  Curr Opin Pediatr       Date:  2010-08       Impact factor: 2.856

2.  Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta.

Authors:  Eva Aström; Håkan Jorulf; Stefan Söderhäll
Journal:  Arch Dis Child       Date:  2006-11-17       Impact factor: 3.791

Review 3.  Osteoporosis.

Authors:  R Cimaz; M Biggioggero
Journal:  Curr Rheumatol Rep       Date:  2001-10       Impact factor: 4.592

4.  Beneficial effect of long term intravenous bisphosphonate treatment of osteogenesis imperfecta.

Authors:  E Aström; S Söderhäll
Journal:  Arch Dis Child       Date:  2002-05       Impact factor: 3.791

5.  Short-term efficacy of monthly pamidronate infusion in patients with osteogenesis imperfecta.

Authors:  Jin-Ho Choi; Young-Lim Shin; Han-Wook Yoo
Journal:  J Korean Med Sci       Date:  2007-04       Impact factor: 2.153

Review 6.  The role of bisphosphonates in diseases of childhood.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  Eur J Pediatr       Date:  2003-09-11       Impact factor: 3.183

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.